Pediatric Clinical Trials Market, by Clinical Trial Phase (Pre-clinical, Phase I, Phase II, and Phase III), by Study Design (Interventional (Randomized Trial, Non-randomized Trial, and Crossover Trial), and Observational), by Medical Condition (Neuropsych

Pediatric Clinical Trials Market, by Clinical Trial Phase (Pre-clinical, Phase I, Phase II, and Phase III), by Study Design (Interventional (Randomized Trial, Non-randomized Trial, and Crossover Trial), and Observational), by Medical Condition (Neuropsychiatric Conditions, Infectious Diseases, Maternal and Perinatal Conditions, Respiratory Diseases, Cardiovascular Diseases, Cancer, Digestive Diseases, Diabetes, Nutritional Deficiencies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Clinical trials generates evidence-based data and knowledge in medicine. Clinical trials conducted on children (between age group of 0 to 18) for research and development of drugs or formation of new drugs are called as pediatric clinical trials. Pharmaceuticals and biotechnological industries and government regulatory bodies are collectively focused on improving research and development for pediatric population. A new law in the U.S. and Europe was passed as pediatric regulation 2007 that required new adult drugs to be tested for use in children. This, in turn, is expected to lead to increasing number of pediatric clinical trials in the U.S. and worldwide.
Market Dynamics
Robust product pipeline, increasing approval of new pediatric drugs, and high outsourcing for drug development are major factors driving the pediatric clinical trials market growth. According to Pharmaceutical Research and Manufacturers’ Association (PHRMA) data in 2018, over 1,300 industry-sponsored pediatric clinical trials are underway across a variety of therapeutic areas, including diseases where there is significant unmet need such as infectious diseases, neurologic conditions, genetic disorders, and several forms of cancer. Similarly, 5 pediatric drugs received the U.S. FDA approval in 2018, and 4 and 7 in 2017 and 2015, respectively.
Moreover, introduction of new approaches in clinical research and implementation of advanced technology is expected to boost the market growth. Adoption of data analytics and machine learning platforms is expected to help in better management of the data generated during trials, which can play key role in faster drug development. For instance, in 2015, Quintiles announced the addition of advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (RBM) solution.
Increasing investment in the research and development by pharma and biotech companies targeting major chronic diseases such as cancer, cardiovascular disease, neuropsychiatry disease, and respiratory disease is expected to drive the market growth over the forecast period. According to a report published by the International Federation of Pharmaceutical Manufacturer and Association in 2017, pharmaceutical industry invested around US$ 149.8 billion on research and development, annually. The companies are downsizing this cost by outsourcing clinical research activities. There are more than 7,000 compounds in preclinical stage of development, out of which around 56 were launched in 2015 and around 225 new chemical and biological entities were launched between 2011 and 2015.
Key features of the study:
This report provides in-depth analysis of the global pediatric clinical trials market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pediatric clinical trials market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global pediatric clinical trials market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pediatric clinical trials market
Detailed Segmentation:
Global Pediatric Clinical Trials Market, By Clinical Trial Phase:
Pre-clinical
Phase I
Phase II
Phase III
Global Pediatric Clinical Trials Market, By Study Design:
Interventional
Randomized Trial
Non-randomized Trial
Crossover Trial
Observational
Global Pediatric Clinical Trials Market, By Medical Condition:
Neuropsychiatric Conditions
Infectious Diseases
Maternal and Perinatal Conditions
Respiratory Diseases
Cardiovascular Diseases
Cancer
Digestive Diseases
Diabetes
Nutritional Deficiencies
Others
Global Pediatric Clinical Trials Market , By Region:
North America
By Clinical Trial Phase:
Pre-clinical
Phase I
Phase II
Phase III
By Study Design:
Interventional
Randomized Trial
Non-randomized Trial
Crossover Trial
Observational
By Medical Condition:
Neuropsychiatric Conditions
Infectious Diseases
Maternal and Perinatal Conditions
Respiratory Diseases
Cardiovascular Diseases
Cancer
Digestive Diseases
Diabetes
Nutritional Deficiencies
Others
By Country:
U.S.
Canada
Latin America
By Clinical Trial Phase:
Pre-clinical
Phase I
Phase II
Phase III
By Study Design:
Interventional
Randomized Trial
Non-randomized Trial
Crossover Trial
Observational
By Medical Condition:
Neuropsychiatric Conditions
Infectious Diseases
Maternal and Perinatal Conditions
Respiratory Diseases
Cardiovascular Diseases
Cancer
Digestive Diseases
Diabetes
Nutritional Deficiencies
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Clinical Trial Phase:
Pre-clinical
Phase I
Phase II
Phase III
By Study Design:
Interventional
Randomized Trial
Non-randomized Trial
Crossover Trial
Observational
By Medical Condition:
Neuropsychiatric Conditions
Infectious Diseases
Maternal and Perinatal Conditions
Respiratory Diseases
Cardiovascular Diseases
Cancer
Digestive Diseases
Diabetes
Nutritional Deficiencies
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Clinical Trial Phase:
Pre-clinical
Phase I
Phase II
Phase III
By Study Design:
Interventional
Randomized Trial
Non-randomized Trial
Crossover Trial
Observational
By Medical Condition:
Neuropsychiatric Conditions
Infectious Diseases
Maternal and Perinatal Conditions
Respiratory Diseases
Cardiovascular Diseases
Cancer
Digestive Diseases
Diabetes
Nutritional Deficiencies
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Clinical Trial Phase:
Pre-clinical
Phase I
Phase II
Phase III
By Study Design:
Interventional
Randomized Trial
Non-randomized Trial
Crossover Trial
Observational
By Medical Condition:
Neuropsychiatric Conditions
Infectious Diseases
Maternal and Perinatal Conditions
Respiratory Diseases
Cardiovascular Diseases
Cancer
Digestive Diseases
Diabetes
Nutritional Deficiencies
Others
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Clinical Trial Phase:
Pre-clinical
Phase I
Phase II
Phase III
By Study Design:
Interventional
Randomized Trial
Non-randomized Trial
Crossover Trial
Observational
By Medical Condition:
Neuropsychiatric Conditions
Infectious Diseases
Maternal and Perinatal Conditions
Respiratory Diseases
Cardiovascular Diseases
Cancer
Digestive Diseases
Diabetes
Nutritional Deficiencies
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Syneos Health Inc. *
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
IQVIA Holdings, Inc.
Charles River Laboratories International Inc.
Covance Inc.
ICON plc.
Pharmaceutical Product Development, LLC.
Genentech (F. Hoffmann-La Roche AG).
Pfizer, Inc.
Bristol - Myers Squibb.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Johnson & Johnson
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited.
Vertex Pharmaceuticals Inc.
“*” marked represents similar segmentation in other categories in the respective section.